https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0717-75262002000300014
MECANISMO DE ACCION DE ANTICONCEPTIVOS ORALES: ¿CUMPLEN LOS ACO DE BAJAS DOSIS CON EL OBJETIVO DE INHIBIR LA OVULACION?

INTRODUCCION 

 

Los anticonceptivos orales (ACO) usados principalmente como método de    planificación familiar tienen también indicaciones terapéuticas.    En casos de algia pelviana secundaria a endometriosis, síndrome premenstrual,    dismenorrea esencial, procesos inflamatorios pelvianos crónicos, el suprimir    la ovulación es un objetivo que cumple con lograr una mejoría    sintomática de estas pacientes (1-3).  

En pacientes que consultan por metrorragia disfuncional o sangramiento uterino    anormal, la utilización de ACO es útil en el manejo sintomático    de estas patologías (4). En el síndrome de ovario    poliquístico -patología hoy en día de diagnóstico    frecuente- los anticonceptivos orales combinados mediante su efecto hormonal    son efectivos en disminuir el hirsutismo y el acné (5).  

Los anticonceptivos orales de altas dosis inicialmente comercializados en la    década del 60 contenían altas dosis de estrógenos y progestágenos.    Los estrógenos y los gestágenos a grandes dosis pueden inhibir    por sí solos la ovulación y utilizados en conjunto, su efecto    sinérgico permite disminuir la dosis de cada uno (6).    La inhibición sobre el eje hipotálamo-hipófisis es dosis    dependiente, a menores dosis, los niveles basales de gonadotrofinas son mayores    (7, 8). Considerando los ACO que poseen etinilestradiol    (EE2) y levonorgestrel (LNG) como progestágeno, ha habido una reducción    de las dosis de ambos compuestos pasando de 50 µg EE2 / 250 µg LNG    a las dosis actuales de 30 µg EE2 / 150 µg LNG. Se conserva una relación    entre ambos de 1:5 que parece ser necesaria para mantener un adecuado balance    en el metabolismo de carbohidratos y lípidos (9). Estos    anticonceptivos que contienen dosis menores de ambos compuestos son llamados    de "microdosis" y contienen actualmente 20 µg EE2 y 100 µg    de LNG. 

Los ACO tienen efecto a distintos niveles en el aparato reproductor femenino.    Estos efectos son los buscados según la finalidad con la que son administrados.  

En primer lugar; al ser utilizados como contraceptivos, además del efecto    antiovulatorio considerado como el mecanismo principal, se describen mecanismos    secundarios que consisten en los efectos sobre la migración espermática    y en el endometrio. Estos mecanismos de acción secundarios actuarían    en la medida que se produzca la ovulación, es decir, que fallara la inhibición    de esta última como mecanismo principal. El efecto endometrial que pudiera    alterar la capacidad de implantación del embrión puede constituirse    como mecanismo anti-implantatorio. Este efecto que impide la nidación    de un embrión en su primera semana del desarrollo, constituye un problema    serio para aquellos que consideran la fertilización como el inicio de    la persona humana. Estas últimas posturas, muchas veces compartidas por    los médicos, se basan en creencias o ideales de orden religioso, cultural    y/o ético-moral. Para que los mecanismos secundarios tengan una real    participación en la eficacia de los ACO como contraceptivos, una de las    primeras preguntas que debe formularse es en qué porcentaje se inhibe    la ovulación en la utilización de ACO. Posteriormente deberá    analizarse la contribución de cada uno de los mecanismos secundarios.  

En segundo lugar la utilización de estos fármacos en el arsenal    terapéutico del médico, persigue inhibir la ovulación,    disminuir la cantidad de sangrado, la dismenorrea, etc. Si la mujer tiene actividad    sexual, aunque sea con motivos diferentes al de la planificación familiar,    la administración del ACO también plantea un problema desde el    punto de vista ético, ya que están en juego los mismos mecanismos    descritos. 

Por último, desde el sólo punto de vista terapéutico es    interesante saber si con los ACO de microdosis (0,020 mg de etinilestradiol)    estamos consiguiendo el objetivo anovulatorio deseado para el tratamiento sintomático    de las pacientes. 

La pregunta que nos hemos efectuado es si con la utilización de ACO    de microdosis se inhibe la ovulación de manera que sea una terapia anovulatoria    eficiente y que no plantee ni al médico ni a la paciente resolver un    problema de orden moral. Para responderla hemos revisado trabajos clínicos    experimentales que puedan ser comparables entre sí y en los cuales se    investiga la supresión de la ovulación en mujeres normales que    ingieren ACO de microdosis. 

 

MATERIAL Y METODO 

 

En esta revisión se buscó literatura desde el año 1985-2001    en diversas revistas médicas de ginecología y MEDLINE bajo los    ítems "anticoncepción hormonal, anticoncepción oral,    e "inhibición de la ovulación", "inhibition of    ovulation", "oral contraceptives" y "ovulation". Se    encontraron 18 trabajos (10-27) en que se    analizaba la actividad ovárica -específicamente la ovulación-    en la utilización de microdosis de ACO monofásicos combinados    continuos de los cuales se eligieron 3 trabajos experimentales (25-27)    que eran comparables entre ellos según los siguientes criterios de inclusión:    1) población semejante en cuanto a edad (18-35 años) y antecedentes    ginecológicos: 2) número de ciclos analizados (5: 1 pretratamiento,    3 en tratamiento y 1 post-tratamiento); 3) el método para determinar    la ovulación en todos los ciclos: ecografía transabdominal o transvaginal,    y análisis hormonal de muestras de sangre (FSH, LH, 17 b estradiol y    progesterona). También se consideró el hecho de que todos fuesen    ACO de bajas dosis de EE2 (20 µg de etinilestradiol) asociados a levenorgestrel,    desogestrel o a gestodene. Todos los estudios se llevaron a cabo sobre un total    de 5 ciclos. En un primer ciclo, sin administración de los fármacos,    se aseguró que las mujeres, en condiciones normales, presentaron ciclos    ovulatorios. Luego se analizan 3 ciclos de tratamiento durante los cuales se    administraron diariamente por 21 días, tabletas que contenían    20 µg de EE2 + 100 µg de LNG, 150 µg de desogestrel o 75 µg    de gestodeno. Finalmente se analizó un último ciclo sin tratamiento.    El primer ciclo de tratamiento comenzó el primer día de sangramiento    menstrual y se continuó durante los 21 días consecutivos; luego    de un intervalo de siete días sin tabletas se recomenzó la administración    exactamente 4 semanas después de la primera píldora. 

Las voluntarias consistían en un grupo de mujeres entre 18 y 35 años    de edad, que cumplían con los criterios de inclusión y exclusión    usuales para el uso de ACO. La actividad ovárica se determinó    según la clasificación ideada por Hoogland y 

Skouby (28) que se basa en los diámetros de las estructuras    folículo símiles y en niveles hormonales plasmáticos en    etapa secretora (Tabla I). Con estos datos se decidió    hacer una tabla comparativa para ilustrar de forma didáctica los resultados.





RESULTADOS 

 

Los resultados de los tres trabajos se resumen en la Tabla    II. En el estudio de Fitzgerald et al (22) de 53    pacientes, inicialmente distribuidas al azar en cada uno de dos grupos de tratamiento,    se analizan 19 mujeres en cada grupo, luego de que 12 no ovularan y 3 se retiraran    durante el primer ciclo sin tratamiento. No se demuestran ovulaciones en los    ciclos tratados. Se evidencia actividad folicular grado 4 y 5 en 11-21% de las    mujeres. Hay una tendencia a una mayor actividad folicular durante el segundo    ciclo de tratamiento. No encuentran diferencia significativa en el número    de ciclos con actividad folicular entre el grupo desogestrel y gestodeno. Los    autores dan los resultados en porcentajes de mujeres sin detallar el número    ni el ciclo de tratamiento en que ocurrió la actividad ovárica.    El estudio de Spona et al (23) se realiza con 71 ciclos    de tratamiento en 23 mujeres que completan el estudio. Tampoco se evidencian    ovulaciones en estos ciclos. Los autores muestran indistintamente datos de ciclos    y de mujeres. En 32,4% de los ciclos de tratamiento se objetiva actividad folicular    grado 4 y 5. La actividad residual se manifiesta principalmente como actividad    tipo 4 (folículos mayores de 13 mm con secreción estrogénica    adecuada pero niveles no ovulatorios de progesterona). En el primer ciclo de    tratamiento 2 de 24 ciclos presentan actividad tipo 4; en el segundo y tercer    ciclo en que se evidencia actividad residual (4 y 5) son un 50% (12 de 24 ciclos)    y 39% (9 de 23 ciclos) respectivamente. Hay entre estos últimos, una    mujer que presenta en el segundo y tercer ciclo una actividad tipo 5 catalogada    como LUF (Lutein Unrupture Follicle). Los diámetros foliculares son mayores    en el segundo y tercer ciclo de tratamiento en comparación con el primero.    No está descrito qué porcentaje de los ciclos que presentan actividad    ovárica pertenecen o no a la misma mujer. La supresión de los    diámetros foliculares es también más manifiesta en el primer    ciclo que en el segundo y tercer ciclo de tratamiento, los autores suponen que    el hecho se corrobora con la mayor actividad folicular observada en esos ciclos    (Figuras 1 y 2).









Figura 1. Número de voluntarias para las cuales se        registró actividad 4 y 5 durante los tres ciclos de tratamiento con        100 µg LNG más 20 µg de EE2 (tomado de Spona et al.        Inhibition of ovulation by an oral contraceptive containing 100 µg        levonorgestrel in combination with 20 µg ethinylestradiol. Contraception        1996; 54: 299-304).





Figura 2. Media de diámetros de estructuras folículo-símiles.        Antes del tratamiento, durante, y luego del tratamiento con 100 µg        de LNG más 20 µg de EE2 (tomado de Spona et al: Inhbition        of ovulation by an oral contraceptive containing 100 µg levonorgestrel        in combination with 20 µg ethinylestradiol. Contraception 1996; 54:        299-304).

Coney et al (24), a diferencia de los 2 trabajos anteriores,    distingue entre ciclos de tratamiento y mujeres. En el 62% de 73 ciclos de tratamiento    y en 81% de 26 mujeres se observan diámetros foliculares mayores de 10    mm lo cual se clasifica como actividad ovárica potencial. Esto se asocia    a niveles de progesterona bajos pero a niveles fluctuantes de estradiol. En    38,4% de los ciclos hay actividad folicular tipo 4, en 2,7% (dos mujeres) tipo    5 y en 2,7% (otras dos mujeres) hay ovulación (Tabla    III). Según el ciclo de tratamiento de las mujeres de la serie, los    diámetros foliculares van aumentando. Coney demuestra ovulación    con folículos de 36 y 18 mm en dos mujeres, en el tercer ciclo de tratamiento,    lo que significa un 8% de las mujeres de su serie.





En todos los trabajos se estudiaron las poblaciones, según    lo enunciado en los criterios de inclusión. Sin embargo, los resultados    en cuanto a número de ovulaciones, que pueden ser referidos a ciclos    o a mujeres no están formulados de igual manera entre los tres trabajos.    Dos de los trabajos no refieren los resultados diferenciados según ciclos    y según mujeres, por lo tanto no es posible tomar el total de mujeres    y de ciclos de las tres series para recalcular todos los parámetros.    Del total de mujeres de las tres series, que terminaron el seguimiento un 2,35%    (dos mujeres de 85 presentaron ovulación pesquisada hormonal y ecográficamente).  

DISCUSION 

 

Durante la administración de ACO secuenciales de dosis bajas, la actividad    ovárica no se inhibe completamente. Grimes (14) en    un estudio clínico experimental describe ovulaciones en usuarias de ACO    que contienen 0,35 mg de estradiol durante los ciclos 5 y 6 de tratamiento,    siendo el porcentaje de ovulación en este grupo tres veces mayor que    en el grupo de ACO trifásicos que contienen 0,50 mg de etinilestradiol.    Teichmann (15) en un estudio de diseño semejante a    los que hemos analizado, objetiva actividad hormonal folicular correspondientes    a grados 4 y 5 en 17 ciclos de los 39 que estudia lo que equivale a un 43% de    los ciclos. No realiza seguimiento folicular en todas ellas lo que no permite    saber el grado de desarrollo folicular y si hay o no ovulaciones. En los trabajos    analizados, un 11 a 20% de las mujeres presentarían actividad folicular    sin llegar a ovular (Fitzgerald) y hasta un 81% de las mujeres presentaron folículos    de más de 10 mm (Coney). Se observa que los diámetros foliculares    van progresivamente aumentando durante los ciclos de tratamiento, al igual que    la actividad ovárica que también aumenta progresivamente hacia    el tercer ciclo de tratamiento. En los trabajos de Fitzgerald y de Spona la    actividad ovárica en el tercer ciclo baja con respecto al segundo, sin    embargo en ambos casos la actividad ovárica en el tercer ciclo es más    elevada que en el primer ciclo. Coney confirma el aumento sucesivo de los diámetros    foliculares durante los ciclos de tratamiento. En otros trabajos también    se ha corroborado la tendencia al aumento de la actividad hormonal folicular    en segundo y tercer ciclo de tratamiento (15). Una primera    conclusión es que el efecto de los ACO de bajas dosis varía durante    el tiempo de exposición y que al revés de lo que pudiera suponerse    en el sentido de que a más tiempo de exposición mayor inhibición    del eje, esto no sucede así en la práctica. En todo caso, el presentar    goteo intermenstrual, más frecuente en el primer ciclo según Fitzgerald,    no es indicativo de mayor o menor actividad ovárica. 

Ya que dos de los trabajos no refieren los resultados diferenciados según    ciclos y según mujeres, no nos es posible tomar todas las mujeres o todos    los ciclos como universo para todos los parámetros. Con los datos disponibles,    y ya que no hay ovulaciones descritas en dos trabajos, sólo es posible    deducir el porcentaje de mujeres que terminaron el seguimiento y que presentaron    ovulación pesquisada hormonal y ecográficamente y que es de un    2,35% (dos mujeres de 85) del número total de mujeres que terminaron    el seguimiento. 

El fenómeno de escape ovulatorio ("breakthrough ovulation")    que ha sido ampliamente documentado y analizado (29) plantea    una disminución de la eficiencia contraceptiva en el uso poblacional    de los ACO con respecto a la eficiencia medida en condiciones ideales. Esto    es también esperable para los ACO de bajas dosis y el hecho de que se    evidencie escape en condiciones ideales hace suponer que también habrá    escape en el uso de los compuestos que nos atañen. 

Aunque el perfil hormonal en fase lútea se utiliza para detectar la    ocurrencia de ovulación, la ecografía transvaginal es actualmente    el medio más utilizado en el diagnóstico de ovulación.    La ecografía transvaginal permite también identificar la ocurrencia    de LUF, en que habiendo desarrollo folicular adecuado y producción de    progesterona adecuada no hay ovulación ni liberación del oocito    para ser fecundado. No se describen ovulaciones en los trabajos de Spona y Fitzgerald.    Coney demuestra ovulación en dos mujeres, lo que significa un 8% de las    mujeres de su serie. No refiere en qué ciclos de tratamiento ocurrieron    las ovulaciones. En el trabajo de Spona una misma paciente presenta LUF en los    ciclos segundo y tercero de tratamiento. Esto significa un 4% aproximadamente    de las mujeres de su serie equivalente a un 2,8% de los ciclos. Coney encuentra    un 2,7% de LUF entre los ciclos, lo cual corresponde a un 8% aproximadamente    (dos casos) de las mujeres de su serie. 

El concepto de LUF es actualmente discutido y el diagnóstico basado    en el monitoreo ecográfico es difícil ya que los signos ecográficos    no son siempre claros (30, 31). Se lo ha    postulado como causa de infertilidad, pero también ha sido descrito en    4,5% de mujeres en edad reproductiva sin problemas de fertilidad por lo que    pudiera ser considerado como una variante biológica (32).    La presencia de LUF podría ser la traducción de un funcionamiento    ovárico relativamente normal, y su ocurrencia en un ciclo particular,    un fenómeno aislado que más bien apoya un contexto de funcionamiento    ovárico normal. La ovulación es posible en mujeres usuarias de    ACO como bien lo confirma la serie de Coney en que un 8% de las mujeres presentaron    ovulación durante los tres primeros ciclos de ingesta de ACO en condiciones    ideales. El hecho de objetivar LUF entre las usuarias de ACO viene a confirmar    el hecho de que la actividad folicular no está inhibida en estas mujeres.    Analizados individualmente, en el trabajo de Spona un 4% de las mujeres presenta    LUF y en el de Coney un 16% de las mujeres presentaron ovulación o LUF.    Fitgerald no describe ni LUF ni ovulaciones, el uso de desogestrel o gestodeno    es lo único que lo diferencia de los otros dos esquemas que utilizan    levonorgestrel. Si esto último es la causa de una mayor inhibición    del eje es un factor que no será analizado en el presente trabajo. 

No fue posible saber en qué medida los ciclos con actividad ovárica    corresponden a las mismas o a distintas pacientes, en ninguno de los trabajos.    Tampoco es posible saber si las pacientes que presentaron ovulación tenían    actividad folicular (tipo 4) en los otros ciclos. Esto permitiría determinar    si hay un grupo o tipo de pacientes en quienes el ACO no inhibe suficientemente    el eje. Dado que en el trabajo de Spona la misma mujer presenta dos veces LUF    pudiera pensarse que existe alguna "predisposición" de ciertas    mujeres a mantener actividad ovárica bajo ACO. Sin embargo, en el trabajo    de Coney las mujeres que presentan LUF son distintas y tampoco son las mismas    que presentan ovulación. 

Toda vez que la ovulación debe ser evitada para paliar síntomas    o tratar patología de base en la mujer, el bajo porcentaje de ciclos    ovulatorios en régimen con ACO de bajas dosis, hacen de éstos    una arma terapéutica efectiva. La actividad folicular residual hasta    de un 81% en la serie de Spona que probablemente mantiene niveles estrogénicos    significativos pudiera dar cuenta de fracasos de tratamiento en patología    que responde a estrógenos como por ejemplo la endometriosis. Frente al    caso individual de una paciente con actividad sexual, entre un mínimo    de 2,35% y un máximo de 8% de las mujeres ovulan dentro de los tres primeros    meses de uso de ACO de bajas dosis, en condiciones ideales. En caso de utilización    prolongada, y en condiciones reales de utilización de contracepción,    existe la posibilidad teórica de ovulaciones que ocurren después    de los seis meses de tratamiento pero se ignora el porcentaje de mujeres en    que ocurre. 

Resolver si la utilización del ACO constituye -eventualmente- un problema    de orden moral para aquellos médicos y pacientes que tienen reparos a    mecanismos de acción post-fertilización, como el antiimplantatorio,    pasa por contestar en qué medida actúan los otros mecanismos secundarios    que impiden el desarrollo de un embarazo. Esta última pregunta -cuya    respuesta no es el objetivo de esta revisión- debiera ser analizada en    base a trabajos que además de contar con casuística adecuada,    analicen qué ocurre con el moco y el endometrio cuando se ha desencadenado    la ovulación, no obstante la administración de ACO de bajas dosis.  

El gran avance tecnológico y la gran disponibilidad de medicamentos    así como de terapias y de formas de control o planificación familiar    se ofrecen a una población de mujeres o pacientes que tienen posturas    antropológicas indefinidas o irrelevantes para el tema del comienzo de    la vida humana y también a una población con posturas particulares    y claramente definidas. Este último grupo de pacientes exige frecuentemente    información respecto del tema, y el médico independientemente    de su opinión personal, debe dar siempre información veraz. Nos    parece que estas cifras son importantes para el manejo de la información    en nuestra relación con la paciente y para la eventual discusión    ética actual sobre el tema. 

BIBLIOGRAFIA 

 

 1. Cohen J: Les dysménorrhées. En: Chapron C,    Benhamou D, Belaisch-Allart J, Dubuisson JB (eds). La douleur en Gynécologie.    Paris: Arnette Blackwell SA 1997; 131-64.         [ Links ] 2. Tamborini A: Les syndromes prémenstruals. En: Chapron    C, Benhamou D, Belaisch-Allart J, Dubuisson JB (eds). La douleur en Gynécologie.    Paris: Arnette Blackwell SA, 1997; 107-24.         [ Links ] 3. Rapkin AJ: Pelvic pain and dysmenorrhea. En: Berek JS,    Adashi EY, Hillard PA (eds). Novak's Gynecology. Baltimore: Williams & Wilkins,    1996; 399-428.         [ Links ] 4. Munro MG: Medical management of abnormal uterine bleeding.    Obstet Gynecol Clin North Am 2000; 27: 287-304.        [ Links ]5. Goldzieher JW: Polycystic ovarian disease. Fertil Steril    1981; 35: 371-94.         [ Links ] 6. Stubblefield PG: Family planning. En: Berek JS, Adashi    EY, Hillard PA (eds). Novak's Gynecology. Baltimore: Williams & Wilkins    1996; 227-78.         [ Links ] 7. Landgren BM: Mechanism of action of gestagens. Int J Gynaecol    Obstet 1990; 32: 95-110.         [ Links ] 8. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier    J: Ovarian function is effectively inhibited by a low dose triphasic oral contraceptive    containing ethinyl estradiol and levonorgestre. Contraception 1984; 29: 305-18.          [ Links ] 9. Arnt IV, Ferrari A, Sartoretto JN, Woutersz TB: Low-dose    combination oral contraceptives: a controlled clinical study of three different    norgestrel-ethinyl estradiol ratios. Fertil Steril 1997; 28: 549-53.         [ Links ]10. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger    U, Walter F, Graser T: Modulation of ovarian function by an oral contraceptive    containing 30 µg ethinyl estradiol in combination with 2.00 mg dienogest.    Contraception 1997; 56: 185-91.         [ Links ]11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

 2. Tamborini A: Les syndromes prémenstruals. En: Chapron    C, Benhamou D, Belaisch-Allart J, Dubuisson JB (eds). La douleur en Gynécologie.    Paris: Arnette Blackwell SA, 1997; 107-24.         [ Links ] 3. Rapkin AJ: Pelvic pain and dysmenorrhea. En: Berek JS,    Adashi EY, Hillard PA (eds). Novak's Gynecology. Baltimore: Williams & Wilkins,    1996; 399-428.         [ Links ] 4. Munro MG: Medical management of abnormal uterine bleeding.    Obstet Gynecol Clin North Am 2000; 27: 287-304.        [ Links ]5. Goldzieher JW: Polycystic ovarian disease. Fertil Steril    1981; 35: 371-94.         [ Links ] 6. Stubblefield PG: Family planning. En: Berek JS, Adashi    EY, Hillard PA (eds). Novak's Gynecology. Baltimore: Williams & Wilkins    1996; 227-78.         [ Links ] 7. Landgren BM: Mechanism of action of gestagens. Int J Gynaecol    Obstet 1990; 32: 95-110.         [ Links ] 8. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier    J: Ovarian function is effectively inhibited by a low dose triphasic oral contraceptive    containing ethinyl estradiol and levonorgestre. Contraception 1984; 29: 305-18.          [ Links ] 9. Arnt IV, Ferrari A, Sartoretto JN, Woutersz TB: Low-dose    combination oral contraceptives: a controlled clinical study of three different    norgestrel-ethinyl estradiol ratios. Fertil Steril 1997; 28: 549-53.         [ Links ]10. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger    U, Walter F, Graser T: Modulation of ovarian function by an oral contraceptive    containing 30 µg ethinyl estradiol in combination with 2.00 mg dienogest.    Contraception 1997; 56: 185-91.         [ Links ]11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

 3. Rapkin AJ: Pelvic pain and dysmenorrhea. En: Berek JS,    Adashi EY, Hillard PA (eds). Novak's Gynecology. Baltimore: Williams & Wilkins,    1996; 399-428.         [ Links ] 4. Munro MG: Medical management of abnormal uterine bleeding.    Obstet Gynecol Clin North Am 2000; 27: 287-304.        [ Links ]5. Goldzieher JW: Polycystic ovarian disease. Fertil Steril    1981; 35: 371-94.         [ Links ] 6. Stubblefield PG: Family planning. En: Berek JS, Adashi    EY, Hillard PA (eds). Novak's Gynecology. Baltimore: Williams & Wilkins    1996; 227-78.         [ Links ] 7. Landgren BM: Mechanism of action of gestagens. Int J Gynaecol    Obstet 1990; 32: 95-110.         [ Links ] 8. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier    J: Ovarian function is effectively inhibited by a low dose triphasic oral contraceptive    containing ethinyl estradiol and levonorgestre. Contraception 1984; 29: 305-18.          [ Links ] 9. Arnt IV, Ferrari A, Sartoretto JN, Woutersz TB: Low-dose    combination oral contraceptives: a controlled clinical study of three different    norgestrel-ethinyl estradiol ratios. Fertil Steril 1997; 28: 549-53.         [ Links ]10. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger    U, Walter F, Graser T: Modulation of ovarian function by an oral contraceptive    containing 30 µg ethinyl estradiol in combination with 2.00 mg dienogest.    Contraception 1997; 56: 185-91.         [ Links ]11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

 4. Munro MG: Medical management of abnormal uterine bleeding.    Obstet Gynecol Clin North Am 2000; 27: 287-304.        [ Links ]5. Goldzieher JW: Polycystic ovarian disease. Fertil Steril    1981; 35: 371-94.         [ Links ] 6. Stubblefield PG: Family planning. En: Berek JS, Adashi    EY, Hillard PA (eds). Novak's Gynecology. Baltimore: Williams & Wilkins    1996; 227-78.         [ Links ] 7. Landgren BM: Mechanism of action of gestagens. Int J Gynaecol    Obstet 1990; 32: 95-110.         [ Links ] 8. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier    J: Ovarian function is effectively inhibited by a low dose triphasic oral contraceptive    containing ethinyl estradiol and levonorgestre. Contraception 1984; 29: 305-18.          [ Links ] 9. Arnt IV, Ferrari A, Sartoretto JN, Woutersz TB: Low-dose    combination oral contraceptives: a controlled clinical study of three different    norgestrel-ethinyl estradiol ratios. Fertil Steril 1997; 28: 549-53.         [ Links ]10. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger    U, Walter F, Graser T: Modulation of ovarian function by an oral contraceptive    containing 30 µg ethinyl estradiol in combination with 2.00 mg dienogest.    Contraception 1997; 56: 185-91.         [ Links ]11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

5. Goldzieher JW: Polycystic ovarian disease. Fertil Steril    1981; 35: 371-94.         [ Links ] 6. Stubblefield PG: Family planning. En: Berek JS, Adashi    EY, Hillard PA (eds). Novak's Gynecology. Baltimore: Williams & Wilkins    1996; 227-78.         [ Links ] 7. Landgren BM: Mechanism of action of gestagens. Int J Gynaecol    Obstet 1990; 32: 95-110.         [ Links ] 8. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier    J: Ovarian function is effectively inhibited by a low dose triphasic oral contraceptive    containing ethinyl estradiol and levonorgestre. Contraception 1984; 29: 305-18.          [ Links ] 9. Arnt IV, Ferrari A, Sartoretto JN, Woutersz TB: Low-dose    combination oral contraceptives: a controlled clinical study of three different    norgestrel-ethinyl estradiol ratios. Fertil Steril 1997; 28: 549-53.         [ Links ]10. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger    U, Walter F, Graser T: Modulation of ovarian function by an oral contraceptive    containing 30 µg ethinyl estradiol in combination with 2.00 mg dienogest.    Contraception 1997; 56: 185-91.         [ Links ]11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

 6. Stubblefield PG: Family planning. En: Berek JS, Adashi    EY, Hillard PA (eds). Novak's Gynecology. Baltimore: Williams & Wilkins    1996; 227-78.         [ Links ] 7. Landgren BM: Mechanism of action of gestagens. Int J Gynaecol    Obstet 1990; 32: 95-110.         [ Links ] 8. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier    J: Ovarian function is effectively inhibited by a low dose triphasic oral contraceptive    containing ethinyl estradiol and levonorgestre. Contraception 1984; 29: 305-18.          [ Links ] 9. Arnt IV, Ferrari A, Sartoretto JN, Woutersz TB: Low-dose    combination oral contraceptives: a controlled clinical study of three different    norgestrel-ethinyl estradiol ratios. Fertil Steril 1997; 28: 549-53.         [ Links ]10. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger    U, Walter F, Graser T: Modulation of ovarian function by an oral contraceptive    containing 30 µg ethinyl estradiol in combination with 2.00 mg dienogest.    Contraception 1997; 56: 185-91.         [ Links ]11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

 7. Landgren BM: Mechanism of action of gestagens. Int J Gynaecol    Obstet 1990; 32: 95-110.         [ Links ] 8. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier    J: Ovarian function is effectively inhibited by a low dose triphasic oral contraceptive    containing ethinyl estradiol and levonorgestre. Contraception 1984; 29: 305-18.          [ Links ] 9. Arnt IV, Ferrari A, Sartoretto JN, Woutersz TB: Low-dose    combination oral contraceptives: a controlled clinical study of three different    norgestrel-ethinyl estradiol ratios. Fertil Steril 1997; 28: 549-53.         [ Links ]10. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger    U, Walter F, Graser T: Modulation of ovarian function by an oral contraceptive    containing 30 µg ethinyl estradiol in combination with 2.00 mg dienogest.    Contraception 1997; 56: 185-91.         [ Links ]11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

 8. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier    J: Ovarian function is effectively inhibited by a low dose triphasic oral contraceptive    containing ethinyl estradiol and levonorgestre. Contraception 1984; 29: 305-18.          [ Links ] 9. Arnt IV, Ferrari A, Sartoretto JN, Woutersz TB: Low-dose    combination oral contraceptives: a controlled clinical study of three different    norgestrel-ethinyl estradiol ratios. Fertil Steril 1997; 28: 549-53.         [ Links ]10. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger    U, Walter F, Graser T: Modulation of ovarian function by an oral contraceptive    containing 30 µg ethinyl estradiol in combination with 2.00 mg dienogest.    Contraception 1997; 56: 185-91.         [ Links ]11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

 9. Arnt IV, Ferrari A, Sartoretto JN, Woutersz TB: Low-dose    combination oral contraceptives: a controlled clinical study of three different    norgestrel-ethinyl estradiol ratios. Fertil Steril 1997; 28: 549-53.         [ Links ]10. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger    U, Walter F, Graser T: Modulation of ovarian function by an oral contraceptive    containing 30 µg ethinyl estradiol in combination with 2.00 mg dienogest.    Contraception 1997; 56: 185-91.         [ Links ]11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

10. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger    U, Walter F, Graser T: Modulation of ovarian function by an oral contraceptive    containing 30 µg ethinyl estradiol in combination with 2.00 mg dienogest.    Contraception 1997; 56: 185-91.         [ Links ]11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

11. Rice CF, Killick SR, Dieben T, Coelingh Bennink H: A comparison    of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel    30 micrograms daily. Hum Reprod 1999; 14: 982-5.         [ Links ]12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

12. Thomas K, Vankrieken L: Inhibition of ovulation by low-dose    monophasic contraceptive containing gestodene. Am J Obstet Gynecol 1990; 163(4    Pt 2): 1404-10.         [ Links ]13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

13. Archer DF, Maheux R, Del Conte A, O'Bren FB: A new low-dose    monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms    and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group    (NALSG). Contraception 1997; 55: 139-44.         [ Links ]14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

14. Grimes D, Godwin A, Rubin A, Smith J, Lacarra M: Ovulation    and follicular development associated with three low-dose oral contraceptives:    a randomized controlled trial. Obstet Gynecol 1994; 83: 29-34.         [ Links ]15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

15. Teichmann A, Martens H, Bordasch C, Petersen G, Lorkowski    G: The effects of a new low-dose combined oral contraceptive containing levonorgestrel    on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1: 245-56.         [ Links ]16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

16. Killick S, Eyong E, Elstein M: Ovarian follicular development    in oral contraceptive cycles. Fertil Steril 1987; 48: 409-13.         [ Links ]17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

17. Spona J, Lachnit-Fixson U, Dusterberg B, Dobianer K: Inhibition    of ovulation by a triphasic gestodene-containing oral contraceptive. Adv Contracept    1993; 9: 187-94.         [ Links ]18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

18. Crosignani PG, Testa G, Vegetti W, Parazzini F: Ovarian    activity during regular oral contraceptive use. Contraception 1996; 54: 271-3.          [ Links ]19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

19. Sullivan H, Furniss H, Spona J, Elstein M: Effect of 21    day and 24 day oral contraceptive regimens containing gestodene (60 µg)    and ethinylestradiol (15 µg) on ovarian activity. Fertil Steril 1999; 72:    115-20.         [ Links ]20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

20. Rosenbaum P, Schmidt W et al: Inhibition of ovulation    by a novel progestogen (drospirenone) alone or in combination with wthinylestradiol.    Eur J Contracept Reprod Health Care 2000; 5: 16-54.         [ Links ]21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

21. Lete I, Morales P: Inhibition of follicular growth by    two different oral contraceptives (monophasic and trphasic) containing ethinylestradiol    and gestodene. Eur J Contracept Reprod Health Care 1997; 2: 187-91.         [ Links ]22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

22. Spona J, Huber J: Efficacy of low-dose oral contraceptives    containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet    Invest 1987; 23: 184-93.         [ Links ]23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

23. Wenzl R, Bennink HC, van Beek A, Spona J, Huber J: Ovulation    inhibition with a combined oral contraceptive containing 1 mg micronized 17    beta-estradiol. Fertil Steril 1993; 60: 616-9.         [ Links ]24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

24. Teichmann A, Brill K, Albring M, Schnitker J, Wojtinek    P, Kustra E: The influence of the dose of ethinylestradiol in oral contraceptive    on follicle growth. Gynecol Endocrinol 1995; 9: 299-305.         [ Links ]25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

25. Fitzgerald C et al: A comparison of the effects    of two monophasic low dose oral contraceptives on the inhibition of ovulation.    Advances in contraception 1994; 10: 5-18.         [ Links ]26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

26. Spona J, Feichtinger W, Kinderman Ch et al: Inhibition    of ovulation by an oral contraceptive containing 100 µg levonorgestrel    in combination with 20 µg ethinylestradiol. Contraception 1996; 54: 299-304.          [ Links ]27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

27. Coney P, DelConte A: The effects on ovarian activity of    a mnofasisc oral contraceptive with 100 µg levonorgestrel and 20 µg    ethinylestradiol. Am J Obstet Gynecol 1999; 181: S53-58.         [ Links ]28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

28. Hoogland HJ, Skouby SO: Ultrasound evaluation of ovarian    activity under oral contraceptive. Contraception 1993; 47: 583-90.         [ Links ]29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

29. Larimore W, Stanford J: Postfertilization effects of the    oral contraceptives and their relationship to informed consent. Arch Fam Med    2000; 9: 126-33.         [ Links ]30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

30. Speroff L, Glass RH, Kase NG: Female infertility. En:    Speroff L, Glass RH, Kase NG (eds). Clinical Gynecologic Endocrinology and Infertility.    Baltimore: Lippincott Williams & Wilkins 1999; 1014-42.         [ Links ]31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

31. Crisosto C, Cheviakoff S: Infertilidad Conyugal. En: Pérez-Sánchez    A (ed). Ginecología. Santiago, Chile: Edit Mediterráneo 1995;    381-97.         [ Links ]32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

32. Kerin JF, Kirby C, Morris D, McEvoy M, Ward B, Cox LW:    Incidence of the luteinized unruptured follicle phenomenon in cycling women.    Fertil Steril 1983; 40: 620-        [ Links ]_______________ *Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002. 

_______________

*Documento recibido en julio de 2002 y acepado para    publicación por el Comité Editor en agosto de 2002.